HMGB1: A Potential Therapeutic Target for Myocardial Ischemia and Reperfusion Injury

Xiaorong Hu,Wenwen Fu,Hong Jiang
DOI: https://doi.org/10.1016/j.ijcard.2011.12.066
IF: 4.039
2012-01-01
International Journal of Cardiology
Abstract:Myocardial ischemia and reperfusion (I/R) injury is well known in therapy for acute coronary syndrome and open heart surgery. Although reperfusion therapy (such as thrombolysis and percutaneous coronary intervention) is essential for the survival of ischemic tissue, reperfusion itself causes additional cellular injury. I/R could cause local myocardial inflammation, accompanying with apoptosis, which could result in myocardial cell damage [ [1] Frangoginis N.G. Smith C.W. Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 31-47 Crossref PubMed Scopus (1704) Google Scholar ]. High mobility group box 1 protein (HMGB1), a highly conserved nuclear protein, could regulate gene transcription and maintain the nucleosome structure. HMGB1 could be passively released from necrotic cell, apoptotic cell or actively secreted by innate immune cells (such as macrophages and monocytes) [ 2 Scaffidi P. Misteli T. Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418: 191-195 Crossref PubMed Scopus (3284) Google Scholar , 3 Bell C.W. Jiang W. Reich C.F. et al. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol. 2006; 291: C1318-C1325 Crossref PubMed Scopus (417) Google Scholar ]. Recently, a present study shows that HMGB1 acts as a novel early mediator of inflammation and participates in the pathogenesis of myocardial I/R injury, and HMGB1 could promote the release of tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), whereas HMGB1 A box peptide (a specific HMGB1 antagonist) could reduce myocardial ischemia and reperfusion injury and inhibit the release of TNF-α and IL-6 [ [4] Andrassy M. Volz H.C. Igwe J.C. et al. High-mobility group box-1 in ischemia–reperfusion injury of the heart. Circulation. 2008; 117: 3216-3226 Crossref PubMed Scopus (518) Google Scholar ]. Meanwhile, lots of drugs have been found to reduce myocardial I/R injury by inhibiting HMGB1 expression, including asperosaponin X [ [5] Jiang W.L. Zhang S.P. Zhu H.B. et al. Cardioprotection of asperosaponin X on experimental myocardial ischemia injury. Int J Cardiol. 2011; https://doi.org/10.1016/j.ijcard.2011.06.010 Abstract Full Text Full Text PDF Scopus (25) Google Scholar ], minocycline [ [6] Hu X. Zhou X. Xu C. et al. Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol. 2011; 654: 274-279 Crossref PubMed Scopus (14) Google Scholar ], ethyl pyruvate, [ [7] Hu X. Cui B. Zhou X. et al. Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep. 2012; 19: 227-231 Crossref Scopus (47) Google Scholar ] etc. These suggested that HMGB1 may play an important role in myocardial I/R injury and inhibiting HMGB1 could reduce myocardial I/R injury.
What problem does this paper attempt to address?